Recent psoriasis developments included study results reporting that psoriasis and acne responded to seasonal variations.
Other developments reported on Healio.com/Dermatology included results of a survey finding that images of psoriasis were as bothersome to participants as herpes labialis in some categories:
Psoriasis, acne respond to seasonal variations
Symptoms of psoriasis and acne significantly cleared during the summer and worsened in the winter, according to recently published study results.
Researchers used physician’s global assessment scores to determine seasonal variation in psoriasis and acne. Data were collected between June 2011 and May 2014 in New England. Read more
Psoriasis, herpes labialis highly stigmatizing, image-based survey reports
Participants of an image-based survey found images of psoriasis to be as bothersome as those of herpes labialis in some categories, according to recently published study results.
Researchers used an image-based questionnaire to study and compare the public’s attitude toward psoriasis, to identify factors that contribute to its stigmatization and to compare perceptions of psoriasis against other common dermatological conditions. Read more
Janssen launches Stelara in the UK for treating psoriasis in adolescents
Janssen-Cilag Ltd. announced the availability of Stelara in the United Kingdom for the treatment of moderate-to-severe plaque psoriasis in adolescents age 12 years and older who have not responded to or are intolerant to other systemic therapies or phototherapies.
The European Commission approved this indication for Stelara (ustekinumab) in June, and the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion in May, according to a press release. Read more
Valeant enters into partnership with AstraZeneca to develop brodalumab for psoriasis
Valeant Pharmaceuticals International announced that it has entered into a collaborative agreement through its affiliate with AstraZeneca, with Valeant being granted rights to develop and commercialize brodalumab.
Brodalumab, an IL-17 receptor monoclonal antibody, is being developed as treatment for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis, according to a press release. Read more
Can-Fite provides update on psoriasis, RA studies
Can-Fite BioPharma Ltd. recently reported financial results for 6 months ending June 30 and gave updates on data from its studies on patients with moderate-to-severe psoriasis and rheumatoid arthritis.
Can-Fite announced it is preparing the protocol for another advanced psoriasis trial based on positive data from its completed phase 2/3 study suggesting CF101 was a potential systematic therapy for patients with moderate-to-severe psoriasis, according to the release. It was announced in the first quarter of 2015 that the study had not met its primary endpoint. Read more